An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

Brian R. Murphy, Susan L. Hall, Arun B. Kulkarni, James E. Crowe, Peter L. Collins, Mark Connors, Ruth A Karron, Robert M. Chanock

Research output: Contribution to journalArticle

Abstract

RSV and PIV3 are responsible for about 30% of severe viral respiratory tract disease leading to hospitilization of infants and children. For this reason, there is a need to develop vaccines effective against these viruses. Since these viruses cause severe disease in early infancy, vaccines must be effective in the presence of maternal antibody. Currently, several strategies for immunization against these viruses are being explored including peptide vaccines, subunit vaccines, vectored vaccines (e.g., vaccinia-RSV or adenovirus-RSV recombinants), and live attenuated virus vaccines. The current status of these approaches is reviewed. In addition, the immunologic basis for the disease potentiation seen in vaccinees immunized with formalin-inactivated RSV during subsequent RSV infection is reviewed. The efficacy of immunization in the presence of maternal antibody is discussed. Much progress for a RSV and PIV3 vaccine has been made and successful immunization against each of these pathogens should be achieved within this decade.

Original languageEnglish (US)
Pages (from-to)13-36
Number of pages24
JournalVirus Research
Volume32
Issue number1
DOIs
StatePublished - 1994

Fingerprint

Human parainfluenza virus 3
Respiratory Syncytial Viruses
Vaccines
Viruses
Immunization
Subunit Vaccines
Mothers
Respiratory Tract Diseases
Respiratory Syncytial Virus Infections
Vaccinia
Attenuated Vaccines
Antibodies
Immune System Diseases
Adenoviridae
Formaldehyde

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Virology

Cite this

Murphy, B. R., Hall, S. L., Kulkarni, A. B., Crowe, J. E., Collins, P. L., Connors, M., ... Chanock, R. M. (1994). An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research, 32(1), 13-36. https://doi.org/10.1016/0168-1702(94)90059-0

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. / Murphy, Brian R.; Hall, Susan L.; Kulkarni, Arun B.; Crowe, James E.; Collins, Peter L.; Connors, Mark; Karron, Ruth A; Chanock, Robert M.

In: Virus Research, Vol. 32, No. 1, 1994, p. 13-36.

Research output: Contribution to journalArticle

Murphy, Brian R. ; Hall, Susan L. ; Kulkarni, Arun B. ; Crowe, James E. ; Collins, Peter L. ; Connors, Mark ; Karron, Ruth A ; Chanock, Robert M. / An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. In: Virus Research. 1994 ; Vol. 32, No. 1. pp. 13-36.
@article{7e24d4d5d768424f95c390a54286e984,
title = "An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines",
abstract = "RSV and PIV3 are responsible for about 30{\%} of severe viral respiratory tract disease leading to hospitilization of infants and children. For this reason, there is a need to develop vaccines effective against these viruses. Since these viruses cause severe disease in early infancy, vaccines must be effective in the presence of maternal antibody. Currently, several strategies for immunization against these viruses are being explored including peptide vaccines, subunit vaccines, vectored vaccines (e.g., vaccinia-RSV or adenovirus-RSV recombinants), and live attenuated virus vaccines. The current status of these approaches is reviewed. In addition, the immunologic basis for the disease potentiation seen in vaccinees immunized with formalin-inactivated RSV during subsequent RSV infection is reviewed. The efficacy of immunization in the presence of maternal antibody is discussed. Much progress for a RSV and PIV3 vaccine has been made and successful immunization against each of these pathogens should be achieved within this decade.",
author = "Murphy, {Brian R.} and Hall, {Susan L.} and Kulkarni, {Arun B.} and Crowe, {James E.} and Collins, {Peter L.} and Mark Connors and Karron, {Ruth A} and Chanock, {Robert M.}",
year = "1994",
doi = "10.1016/0168-1702(94)90059-0",
language = "English (US)",
volume = "32",
pages = "13--36",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

AU - Murphy, Brian R.

AU - Hall, Susan L.

AU - Kulkarni, Arun B.

AU - Crowe, James E.

AU - Collins, Peter L.

AU - Connors, Mark

AU - Karron, Ruth A

AU - Chanock, Robert M.

PY - 1994

Y1 - 1994

N2 - RSV and PIV3 are responsible for about 30% of severe viral respiratory tract disease leading to hospitilization of infants and children. For this reason, there is a need to develop vaccines effective against these viruses. Since these viruses cause severe disease in early infancy, vaccines must be effective in the presence of maternal antibody. Currently, several strategies for immunization against these viruses are being explored including peptide vaccines, subunit vaccines, vectored vaccines (e.g., vaccinia-RSV or adenovirus-RSV recombinants), and live attenuated virus vaccines. The current status of these approaches is reviewed. In addition, the immunologic basis for the disease potentiation seen in vaccinees immunized with formalin-inactivated RSV during subsequent RSV infection is reviewed. The efficacy of immunization in the presence of maternal antibody is discussed. Much progress for a RSV and PIV3 vaccine has been made and successful immunization against each of these pathogens should be achieved within this decade.

AB - RSV and PIV3 are responsible for about 30% of severe viral respiratory tract disease leading to hospitilization of infants and children. For this reason, there is a need to develop vaccines effective against these viruses. Since these viruses cause severe disease in early infancy, vaccines must be effective in the presence of maternal antibody. Currently, several strategies for immunization against these viruses are being explored including peptide vaccines, subunit vaccines, vectored vaccines (e.g., vaccinia-RSV or adenovirus-RSV recombinants), and live attenuated virus vaccines. The current status of these approaches is reviewed. In addition, the immunologic basis for the disease potentiation seen in vaccinees immunized with formalin-inactivated RSV during subsequent RSV infection is reviewed. The efficacy of immunization in the presence of maternal antibody is discussed. Much progress for a RSV and PIV3 vaccine has been made and successful immunization against each of these pathogens should be achieved within this decade.

UR - http://www.scopus.com/inward/record.url?scp=0028296935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028296935&partnerID=8YFLogxK

U2 - 10.1016/0168-1702(94)90059-0

DO - 10.1016/0168-1702(94)90059-0

M3 - Article

VL - 32

SP - 13

EP - 36

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 1

ER -